Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ABUS
Strong BuyFLAGArbutus Biopharma Corporation · Healthcare · United States · $1.0B · Avg Vol: $15M/d
Arbutus Biopharma clears the floors at Q59 V58 M54 but none of the all-three-above-60 path is met and there is no corroborating filing, so stage one fails.
COMPANY DESCRIPTION
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapeutics for chronic hepatitis B virus (HBV) infection. The company's competitive advantage stems from its proprietary pipeline of differentiated drug candidates, including RNA interference (RNAi) and capsid assembly inhibitors, which target multiple stages of the HBV lifecycle and address a significant global unmet medical need within a specialized therapeutic area.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.0M | 39.0M | 18.1M | 6.2M | 14.1M | 6.4% | 181.7M | 252.8M | 5.7M | -36.4% |
| EPS | -0.83 | -0.46 | -0.44 | -0.38 | -0.17 | — | 0.79 | 1.03 | -0.11 | — |
| Shares | 145.0M | 157.5M | 169.9M | 190.0M | 192.5M | +32.8% | 198.1M | — | — | — |
| Debt | 2.6M | 2.2M | 1.8M | 1.3M | 0.7M | -26.9% | 3.6M | — | — | — |
| Equity | 169.4M | 136.9M | 106.0M | 97.4M | 76.6M | -18.0% | — | — | — | — |
| Op CF | -67.5M | -35.4M | -85.9M | -64.8M | -39.6M | — | -24.6M | — | — | — |
| Inv CF | -12.7M | -74.9M | 50.8M | 22.9M | 15.6M | — | — | — | — | — |
| Fin CF | 137.2M | 31.8M | 30.6M | 52.0M | 5.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ABUS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ABUS | Arbutus Biopharma Corporation(you) | $1.0B | 84 | Strong Buy |
| ZVRA | Zevra Therapeutics, Inc. | $692M | 87 | Strong Buy |
| TBPH | Theravance Biopharma, Inc. | $883M | 71 | Buy |
| INVA | Innoviva, Inc. | $1.5B | 93 | Strong Buy |
| QTTB | Q32 Bio Inc. | $487M | 88 | Strong Buy |
| RIGL | Rigel Pharmaceuticals, Inc. | $843M | 99 | Strong Buy |
| MGTX | MeiraGTx Holdings plc | $1.4B | 71 | Buy |
| AGEN | Agenus Inc. | $345M | 84 | Strong Buy |
| CRMD | CorMedix Inc. | $645M | 98 | Strong Buy |
| MDXG | MiMedx Group, Inc. | $622M | 70 | Buy |
Peer medians: ROE -25.8% · P/E 29.6x · Gross margin 58.7%